Atara Biotherapeutics ( ATRA ) had its Relative Strength ( RS ) Rating upgraded from 90 to 93 Friday.
[ibd-display-video id=2368044 width=50 float=left autostart=true] IBD's proprietary RS Rating tracks market leadership by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
History shows that the market's biggest winners tend to have an RS Rating north of 80 in the early stages of their moves.
Looking For Winning Stocks? Try This Simple Routine
Atara Biotherapeutics is working on a cup without handle with a 23.10 buy point . See if the stock can break out in volume at least 40% higher than normal.
Taking a look at top and bottom line numbers, the company has posted rising EPS growth over the last two quarters. Sales growth has been a different story, coming in at 0% in the most recent quarterly report.
The company holds the No. 91 rank among its peers in the Medical-Biomed/Biotech industry group. Corcept Therapeutics ( CORT ), Vertex Pharmaceuticals ( VRTX ) and Ligand Pharmaceuticals ( LGND ) are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
